



Research article

Anti-inflammatory and antifatigue effect of Korean Red Ginseng in patients with nonalcoholic fatty liver disease[☆]



Meegun Hong^{1,☆☆}, Yoon Hyeong Lee^{1,☆☆}, Seungwoo Kim^{2,☆☆,*}, Ki Tae Suk^{1,3,*},
Chang Seok Bang¹, Jai Hoon Yoon¹, Gwang Ho Baik¹, Dong Joon Kim¹, Myong Jo Kim⁴

¹ Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea

² Department of Biomedical Science, Hallym University College of Medicine, Chuncheon, Korea

³ Department of Medicine, Columbia University, New York, NY, USA

⁴ College of Agriculture and Life Science, Kangwon National University, Chuncheon, Korea

ARTICLE INFO

Article history:

Received 18 March 2015
Received in Revised form
15 July 2015
Accepted 24 July 2015
Available online 4 August 2015

Keywords:

adiponectin
chronic hepatitis
fatty liver
Panax ginseng

ABSTRACT

Background: Korean Red Ginseng (KRG) is a well-known natural product with anticarcinogenic and antioxidant effects. We evaluated the antifatigue effect of KRG in patients with nonalcoholic fatty liver disease (NAFLD).

Methods: Eighty patients with NAFLD were prospectively randomized to receive 3 wk of KRG or placebo in addition to counseling on healthy eating and regular exercise. Liver function test, proinflammatory cytokines, adiponectin, antioxidant activity, and fatigue score were measured and compared according to the body mass index between the KRG and placebo groups.

Results: The liver function tests were significantly improved after 3 wk of treatment in both groups. The mean levels (at baseline and after treatment) of tumor necrosis factor- α were 108.0 pg/mL \pm 54.8 pg/mL and 92.7 pg/mL \pm 39.0 pg/mL ($p = 0.018$) in the KRG group and 123.1 pg/mL \pm 42.1 pg/mL and 127.5 pg/mL \pm 62.2 pg/mL ($p = 0.694$) in the placebo group, respectively. There was a significant difference in change of adiponectin levels between the KRG (7,751.2 pg/mL \pm 3,108.1 pg/mL and 8,197.3 pg/mL \pm 2,714.5 pg/mL) and placebo groups (7,711.6 pg/mL \pm 3,041.3 pg/mL and 7,286.1 pg/mL \pm 5,188.7 pg/mL, $p = 0.027$). In patients with overweight, the fatigue score was significantly decreased in the KRG group (35.0 \pm 13.2 and 24.5 \pm 8.9, $p = 0.019$).

Conclusion: Our results show that KRG might be effective in reducing proinflammatory cytokine and fatigue in overweight patients with NAFLD, in addition to improvements in adiponectin levels.

Copyright © 2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Fatty liver is defined as a condition in which triglycerides accumulate in hepatocytes to the extent that they comprise over 5% of the mass of the liver. It is divided into alcoholic fatty liver disease and nonalcoholic fatty liver disease (NAFLD) [1,2]. NAFLD and nonalcoholic steatohepatitis are major global public health

problems, because they are related to insulin resistance, obesity, and metabolic syndrome [3]. Most NAFLD patients show chronic fatigue with peripheral inflammation and immune activation, which causes serious social, economic, or medical problems and impairs physical function [4,5].

The World Health Organization defines being overweight as having a body mass index (BMI) of 25 kg/m² or more, whereas a

* Corresponding author. Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Sakju-ro 77, Chuncheon, 24253, Korea.

E-mail address: ktsuk@hallym.ac.kr (K.T. Suk).

☆ ClinicalTrials.gov: Trial Registration number NCT02331589 (<http://clinicaltrials.gov/ct2/show/NCT02331589>).

☆☆ M.H., Y.H.L., and S.K. contributed equally to this study.

BMI of 30 kg/m² or more is considered to indicate obesity. Being overweight or obese significantly increases the risk of developing metabolic syndrome and liver disease [6]. In Western countries, 20–30% of NAFLD patients develop hepatocellular carcinoma [7]. Many overweight patients have been found to suffer from excessive daytime sleepiness [8]. Ginseng (*Panax ginseng* Meyer) root has been widely used as an herbal treatment in East Asia for more than 2,000 yr. Several studies have demonstrated that ginseng has anticarcinogenic, anti-inflammatory, and antioxidant activities, which were associated with fatigue syndrome [9,10].

Ginsenoside Rb1, the most abundant ginsenoside in the herb, activates 5'-adenosine monophosphate-activated protein kinase, which suppresses the expression of genes that encode lipogenesis-inducing enzymes in rats with fatty liver disease [11]. Moreover, ginseng has been used to treat cancer-related fatigue without significant side effects [12]. Based on these findings, it is conceivable that ginseng might contribute to reduce fatigue by modulating inflammation and signal pathway in NAFLD patients. Some studies have demonstrated the antifatigue effect of ginseng [13,14]. However, few studies have evaluated whether ginseng has a direct effect on fatigue resulting from liver disease or on the biomarker of liver disease. Therefore, in this study, we evaluated the anti-inflammatory antioxidant, and antifatigue activities of Korean Red Ginseng (KRG) in patients with NAFLD.

2. Materials and methods

2.1. Patients

Between April 2011 and August 2012, we conducted a single-blind, randomized, controlled clinical trial evaluating the efficacy of KRG (trial registration number: NCT02331589; <http://clinicaltrials.gov/ct2/show/NCT02331589>). Patients aged over 20 yr and with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels of 50 IU/L or more were enrolled. Patients who had viral hepatitis, alcoholic hepatitis, autoimmune hepatitis, pancreatitis, hemochromatosis, Wilson's disease, drug-induced liver injury, or cancers were excluded. The study protocol conformed to the ethical guidelines of the 1975 Helsinki Declaration as reflected by *a priori* approval of the Institutional Review Board for Human Research in all participating hospitals. Informed consent for study participation was obtained from each patient.

Randomization was performed using a computerized procedure. A total of 80 patients were enrolled. Among them, 14 patients (5 patients in the KRG group and 9 patients in the placebo group) were excluded (8 patients refused to participate, 4 patients had inadequate records, and 2 patients were consuming alcohol; Fig. 1). The levels of liver enzymes, proinflammatory cytokines [tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6)], adiponectin, antioxidant activity, and fatigue severity score were measured at the beginning of the study (baseline) and after 3 wk of medication (Fig. 2). We performed subgroup analysis by dividing the overweight and normal groups by BMI, because a previous report suggested that obesity was closely associated with fatigue [15].

We conducted a baseline evaluation, which included obtaining data for the following: family history, BMI, abdominal ultrasound results, a complete blood count, a liver function test, and viral markers. Serum biochemical parameters included total bilirubin (TB), ALT, AST, gamma-glutamyl transpeptidase (γ -GT), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), albumin, blood urea nitrogen, α 1-antitrypsin, creatinine, α -fetoprotein, prothrombin time, blood glucose, triglycerides, total protein (TP), and total cholesterol. All patients were tested for several hepatitis viruses and human immunodeficiency virus. Hepatitis A virus was detected using antihepatitis A IgG and IgM antibodies, and hepatitis B virus was detected using the IgM antibody against the hepatitis B core antigen, the hepatitis B surface antigen, and the hepatitis B surface antibody. Hepatitis E virus was detected using antihepatitis E IgG and IgM antibodies, and hepatitis C virus was detected using antihepatitis C antibodies with or without the presence of hepatitis C RNA.

2.2. Medical treatment

All patients were treated with *Silybum marianum* (Legalon, Bukwang Pharmaceutical, Co., Ltd., Seoul, South Korea) capsule (450 mg/d) and all patients were advised by the same clinician (K.T.S.) to perform regular aerobic exercise for more than 30 min/d. In addition, all patients also received counseling on healthy eating. Patients who met the inclusion criteria were randomly assigned to receive a KRG capsule (ginsenosides Rg1 + Rb1 6.0 mg/g; 3,000 mg/d) or a placebo three times a day for 3 wk (Fig. 2). No other medication was prescribed. The placebos were manufactured at the Korea Ginseng Corporation (Seoul, South Korea), and resembled the KRG capsule powder in both shape and size.




Fig. 1. Flow chart for enrollment. ALT, alanine aminotransferase; AST, aspartate aminotransferase; KRG, Korean Red Ginseng.




Fig. 2. Study design. IL-6, interleukin-6; KRG, Korean Red Ginseng; TNF- α , tumor necrosis factor- α .

2.3. Cytokines and adiponectin

For the measurements of cytokines and adiponectin, serum was processed using the TNF alpha human ELISA kit (ab100654; Abcam, Inc., Cambridge, United Kingdom), the IL-6 human ELISA kit (ab100572; Abcam, Inc.), and the adiponectin human ELISA kit (ab99968; Abcam, Inc.). All procedures were performed according to the manufacturer’s instructions.

2.4. Antioxidant activity

A potentiometric method was used for the calculation of serum antioxidant activity. The value of antioxidant activity was measured as the redox potential difference of the $K_3[Fe(CN_6)]/K_4[Fe(CN_6)]$ mediator system using an antioxidant activity measuring device (IVA Co. Ltd., Yekaterinburg, Russia). Concentrations of antioxidant activity were calculated using the following equation: antioxidant activity (ng/mL) = $\pm(C_{ox} - \alpha C_{red}) / (1 + \alpha)$, where C_{ox} is the concentration of the oxidized form of the mediator (mol/L), C_{red} is the concentration of the reduced form of the mediator (mol/L); and α is equal to $10^{(E_1 - E)/b}$, where b is equal to $2.3RT/nF$, R is the gas constant, T is the temperature (K), n is the electron number ($n = 1$), F is the Faraday constant, and E and E_1 are the potentials (V) of the mediator system before and after the addition of the serum, respectively.

In this study, the standard solution consisted of 0.01M $K_3[Fe(CN_6)]$ and 0.1mM $K_4[Fe(CN_6)]$ in a phosphate buffer solution (pH 7.2). To measure the redox potential within the solution, a platinum electrode and an Ag/AgCl electrode were used as the working electrode and the reference electrode, respectively. First, the value of E was measured for the 2 mL standard solution. Next, 0.4 mL of serum was added to the standard solution and the new redox potential E_1 was measured. Based on the difference between E and E_1 , the value of antioxidant activity was quantitatively estimated using the aforementioned equation [16].

2.5. Fatigue Severity Scale

We used the Krupp Fatigue Severity Scale [17]. The survey had the following nine questions: (1) my motivation is lower when I am fatigued; (2) exercise brings on my fatigue; (3) I am easily fatigued; (4) fatigue interferes with my physical functioning; (5) fatigue causes frequent problems for me; (6) my fatigue prevents sustained physical functioning; (7) fatigue interferes with carrying out certain duties and responsibilities; (8) fatigue is among my three most disabling symptoms; and (9) fatigue interferes with my work, family, or social life. All patients scored each question on a 7-point scale (1 = strongly disagree, 4 = neither disagree nor agree, and

7 = strongly agree). All answers were collected and calculated by one research nurse in the Department of Internal Medicine.

2.6. Statistical analysis

This study is a clinical trial that evaluated fatigue and other outcomes in patients with nonalcoholic steatohepatitis. Therefore, we assumed the sample size by calculating with the difference of 0.7 and standard deviation (SD) of 1 in the fatigue score. A total of 60 patients were needed for this study. The primary outcome was change in liver enzyme levels and fatigue scale score at 3 wk. The secondary outcomes were improvement of cytokines, adiponectin, and antioxidant activities.

All data were expressed as mean \pm SD unless otherwise stated. Significance was evaluated with a paired t test, independent samples t test, and analysis of covariance. Statistical significance was observed when $p < 0.05$. Data obtained from routine blood tests were analyzed with statistical software (SPSS, version 19.0, SPSS, Inc., Chicago, IL, USA) and GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA).

3. Results

3.1. Patient characteristics

Sixty-six patients (35 patients in the KRG group and 31 in the placebo group) completed the study. The mean age was 49.4

Table 1 Clinical characteristics of patients

Variables	All patients (n = 66)		
Male	56 (74.7)		
Age (yr)	47.8 \pm 14.9		
BMI (kg/m ²)	27.9 \pm 4.9		
	Day 1	Day 21	p
AST (IU/L)	55.3 \pm 33.7	41.7 \pm 24.5	< 0.001
ALT (IU/L)	81.3 \pm 38.5	60.7 \pm 36.8	< 0.001
γ -GT (IU/L)	122.5 \pm 145.7	107.8 \pm 208.2	0.243
LDH (IU/L)	223.0 \pm 76.0	201.3 \pm 39.1	0.035
TB (mg/dL)	0.7 \pm 0.2	0.7 \pm 0.2	0.292
Cholesterol (mg/dL)	195.6 \pm 66.8	182.8 \pm 46.7	0.010
ALP (IU/L)	90.3 \pm 42.2	87.2 \pm 38.0	0.273
Albumin (g/dL)	4.5 \pm 0.4	4.6 \pm 0.5	0.695
Total protein (g/dL)	7.1 \pm 0.5	7.1 \pm 0.5	0.842
Glucose (mg/dL)	131.1 \pm 67.0	125.3 \pm 42.5	0.391

Data are presented as n (%) or mean \pm SD. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; LDH, lactate dehydrogenase; TB, total bilirubin; γ -GT, gamma-glutamyl transferase.

Table 2
Changes in liver function tests

	KRG (n = 35)			Placebo (n = 31)			p*
	Pre	Post	p	Pre	Post	p	
BMI (kg/m ²)	26.8 ± 3.8			27.4 ± 4.7			0.610
AST (IU/L)	52.1 ± 30.6	37.3 ± 14.5	0.024	59.1 ± 37.2	47.1 ± 32.2	0.008	0.171
ALT (IU/L)	81.0 ± 43.7	56.9 ± 36.5	0.013	81.6 ± 32.2	65.1 ± 37.2	0.026	0.374
γ-GT (IU/L)	106.9 ± 68.6	81.3 ± 56.7	0.012	139.3 ± 198.2	136.4 ± 294.3	0.902	0.574
LDH (IU/L)	226.7 ± 99.0	200.3 ± 35.4	0.135	218.6 ± 34.1	202.5 ± 43.8	0.063	0.748
TB (mg/dL)	0.7 ± 0.2	0.7 ± 0.2	0.939	0.7 ± 0.2	0.6 ± 0.2	0.045	0.081
Cholesterol (mg/dL)	197.4 ± 39.1	186.1 ± 31.4	0.110	193.6 ± 88.2	179.4 ± 59.4	0.043	0.493
ALP (IU/L)	92.2 ± 54.0	86.7 ± 45.2	0.209	88.1 ± 22.2	87.8 ± 28.0	0.925	0.414
Albumin (g/dL)	4.6 ± 0.3	4.7 ± 0.6	0.305	4.5 ± 0.4	4.4 ± 0.4	0.190	0.108
TP (g/dL)	7.1 ± 0.4	7.2 ± 0.5	0.507	7.1 ± 0.6	7.0 ± 0.6	0.240	0.125
Glucose (mg/dL)	125.9 ± 64.5	119.8 ± 39.5	0.470	137.1 ± 70.4	131.6 ± 45.7	0.621	0.399

Data are presented as mean ± SD.

* comparison between KRG and placebo.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; KRG, Korean Red Ginseng; LDH, lactate dehydrogenase; TB, total bilirubin; TP, total protein; γ-GT, gamma-glutamyl transferase.

yr ± 12.2 yr and 50 patients (75.8%) were men. The patients' baseline characteristics are outlined in Table 1. Fifty-six patients (84.9%) had been diagnosed with fatty liver and acute hepatitis. The mean serum levels of AST, ALT, LDH, and cholesterol were significantly decreased after 3 wk (Table 1).

3.2. Blood test

In the KRG group, the mean (from baseline to after 3 wk) levels of AST (from 52.1 IU/L ± 30.6 IU/L to 37.3 IU/L ± 14.5 IU/L), ALT (from 81.0 IU/L ± 43.7 IU/L to 56.9 IU/L ± 36.5 IU/L), and γ-GT (from 106.9 IU/L ± 68.6 IU/L to 81.3 IU/L ± 56.7 IU/L) improved after KRG therapy ($p < 0.05$). However, the levels of LDH, TB, cholesterol, ALP,

albumin, TP, and glucose were not significantly different from the baseline to after 3 wk of KRG therapy (Table 2). Patients with a BMI of 25 kg/m² or more who underwent KRG therapy showed particularly improved mean levels of ALT (from 83.7 IU/L ± 47.9 IU/L to 55.8 IU/L ± 24.6 IU/L) and γ-GT (from 112.6 IU/L ± 71.2 IU/L to 79.1 IU/L ± 63.9 IU/L; $p < 0.05$). Although patients in the KRG group with a BMI less than 25 kg/m² did show improved mean levels of ALT (from 69.5 IU/L ± 23.3 IU/L to 57.3 IU/L ± 55.0 IU/L) and γ-GT (from 97.4 IU/L ± 73.4 IU/L to 83.5 IU/L ± 47.2 IU/L), the differences were not statistically significant ($p > 0.05$; Table 3).

In the placebo group, the mean levels of AST (from 59.1 IU/L ± 37.2 IU/L to 47.1 IU/L ± 32.2 IU/L) and ALT (from 81.6 IU/L ± 32.2 IU/L to 65.1 IU/L ± 37.2 IU/L) improved after placebo therapy

Table 3
Changes in liver function tests in difference of BMI

	BMI ≥ 25 kg/m ²						p*
	KRG (n = 24)			Placebo (n = 18)			
	Pre	Post	p	Pre	Post	p	
BMI (kg/m ²)	28.3 ± 3.1			29.8 ± 4.0			0.214
AST (IU/L)	55.5 ± 35.4	37.9 ± 13.9	0.053	51.4 ± 26.1	48.3 ± 30.7	0.438	0.119
ALT (IU/L)	83.7 ± 47.9	55.8 ± 24.6	0.031	76.6 ± 24.4	70.4 ± 37.8	0.482	0.146
γ-GT (IU/L)	112.6 ± 71.2	79.1 ± 63.9	0.024	148.3 ± 235.1	166.0 ± 381.9	0.661	0.214
LDH (IU/L)	233.6 ± 113.8	201.7 ± 35.9	0.192	212.8 ± 33.0	207.3 ± 54.2	0.661	0.567
TB (mg/dL)	0.7 ± 0.2	0.7 ± 0.2	0.827	0.7 ± 0.2	0.6 ± 0.2	0.007	0.030
Cholesterol (mg/dL)	201.3 ± 37.7	183.2 ± 31.8	0.066	194.1 ± 45.9	180.1 ± 36.3	0.051	0.001
ALP (IU/L)	96.3 ± 64.0	86.7 ± 53.4	0.113	83.7 ± 22.0	87.9 ± 35.3	0.449	0.155
Albumin (g/dL)	4.5 ± 0.2	4.6 ± 0.6	0.540	4.6 ± 0.3	4.6 ± 0.4	0.326	0.399
TP (g/dL)	7.1 ± 0.3	7.1 ± 0.4	0.795	7.2 ± 0.5	7.2 ± 0.4	0.704	0.799
Glucose (mg/dL)	126.7 ± 71.1	124.4 ± 43.0	0.843	134.8 ± 70.0	125.4 ± 43.9	0.456	0.827
	BMI < 25 kg/m ²						p*
	KRG (n = 11)			Placebo (n = 13)			
	Pre	Post	p	Pre	Post	p	
BMI (kg/m ²)	22.8 ± 2.6			22.9 ± 1.2			0.965
AST (IU/L)	38.6 ± 5.5	36.1 ± 14.9	0.668	54.1 ± 25.2	36.8 ± 19.2	0.054	0.519
ALT (IU/L)	69.5 ± 23.3	57.3 ± 55.0	0.501	76.6 ± 36.6	48.6 ± 24.6	0.083	0.593
γ-GT (IU/L)	97.4 ± 73.4	83.5 ± 47.2	0.236	65.1 ± 49.1	55.9 ± 49.9	0.545	0.645
LDH (IU/L)	220.5 ± 62.2	197.0 ± 40.1	0.393	218.1 ± 28.1	199.1 ± 30.0	0.026	0.897
TB (mg/dL)	0.7 ± 0.3	0.6 ± 0.2	0.413	0.6 ± 0.2	0.7 ± 0.2	0.592	0.585
Cholesterol (mg/dL)	185.0 ± 47.0	182.9 ± 27.1	0.822	147.9 ± 47.1	148.8 ± 30.9	0.911	0.067
ALP (IU/L)	80.9 ± 20.2	87.5 ± 22.1	0.109	93.4 ± 27.2	83.9 ± 18.4	0.129	0.059
Albumin (g/dL)	4.7 ± 0.4	4.9 ± 0.4	0.433	4.2 ± 0.4	4.2 ± 0.5	0.468	0.057
TP (g/dL)	7.2 ± 0.6	7.5 ± 0.6	0.259	6.9 ± 0.7	6.6 ± 0.7	0.139	0.037
Glucose (mg/dL)	129.5 ± 55.7	111.6 ± 33.1	0.124	124.5 ± 33.1	137.1 ± 50.4	0.536	0.168

Data are presented as mean ± SD.

* comparison between KRG and placebo.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; KRG, Korean Red Ginseng; LDH, lactate dehydrogenase; TB, total bilirubin; TP, total protein; γ-GT, gamma-glutamyl transferase.

($p < 0.05$). However, the levels of γ -GT, LDH, ALP, albumin, TP, and glucose did not show significant changes after 3 wk. There were significant changes in the levels of TB and cholesterol, but these were still within the normal range (Table 2).

3.3. Cytokines and adiponectin

The mean IL-6 levels from baseline to after 3 wk changed as follows: from 2.3 ng/mL \pm 1.9 ng/mL to 1.7 ng/mL \pm 0.7 ng/mL ($p = 0.141$) in the KRG group and from 1.5 ng/mL \pm 0.4 ng/mL to 3.8 ng/mL \pm 8.0 ng/mL ($p = 0.209$) in the placebo group. The two groups did not show a statistically significant difference with regard to the change in IL-6 levels ($p = 0.227$; Fig. 3).

The mean TNF- α levels from baseline to after 3 wk changed as follows: from 108.0 pg/mL \pm 54.8 pg/mL to 92.7 pg/mL \pm 39.0 pg/mL ($p = 0.018$) in the KRG group and from 123.1 pg/mL \pm 42.1 pg/mL to 127.5 pg/mL \pm 62.2 pg/mL ($p = 0.694$) in the placebo group. There was a significant difference in the change in TNF- α levels between the KRG and placebo groups ($p = 0.031$; Fig. 3). The mean TNF- α levels in patients with a BMI of 25 kg/m² or more showed particular improvement after KRG

therapy (116.8 pg/mL \pm 63.7 pg/mL to 92.6 pg/mL \pm 41.6 pg/mL; $p = 0.010$). However, in patients with a BMI less than 25 kg/m² who received KRG therapy, the mean TNF- α levels changed from 101.1 pg/mL \pm 31.0 pg/mL to 99.5 pg/mL \pm 41.1 pg/mL, which was not a statistically significant change ($p = 0.824$; Fig. 3).

The mean adiponectin levels from baseline to after 3 wk changed as follows: from 7,751.2 pg/mL \pm 3,108.1 pg/mL to 8,197.3 pg/mL \pm 2,714.5 pg/mL ($p = 0.109$) in the KRG group and from 7,711.6 pg/mL \pm 3,041.3 pg/mL to 7,286.1 pg/mL \pm 5,188.7 pg/mL ($p = 0.717$) in the placebo group. There was a significant difference in the change of adiponectin levels between the KRG and placebo groups ($p = 0.027$; Fig. 3). This was particularly noticeable in patients with a BMI of 25 kg/m² or more, in whom the mean adiponectin levels changed from 7,799.6 pg/mL \pm 3,003.3 pg/mL to 8,326.9 pg/mL \pm 2,445.2 pg/mL ($p = 0.186$) in the KRG group and from 6,869.5 pg/mL \pm 2,176.8 pg/mL to 6,306.5 pg/mL \pm 2,052.0 pg/mL ($p = 0.373$) in the placebo group. There was a significant difference in the change of adiponectin levels in patients with a BMI of 25 kg/m² or more within the KRG group from baseline to 3 wk of treatment ($p = 0.017$; Fig. 3).




Fig. 3. Changes in cytokines and adiponectin. There was a significant difference in the change in TNF- α and adiponectin levels between the KRG and placebo groups. The mean TNF- α and adiponectin levels in patients with a BMI of 25 kg/m² or more showed particular improvement after KRG therapy. BMI, body mass index; IL-6, interleukin-6; KRG, Korean Red Ginseng; ns, not significant; TNF- α , tumor necrosis factor- α .




Fig. 4. Changes in antioxidant activity. No statistically significant difference in the change of antioxidant activity was observed between the two groups. BMI, body mass index; KRG, Korean Red Ginseng; ns, not significant.

3.4. Antioxidant activity

The mean antioxidant activity from baseline to after 3 wk changed as follows: from $1.3 \text{ ng/mL} \pm 0.3 \text{ ng/mL}$ to $1.3 \text{ ng/mL} \pm 0.3 \text{ ng/mL}$ ($p = 0.467$) in the KRG group and from $1.3 \text{ ng/mL} \pm 0.4 \text{ ng/mL}$ to $1.3 \text{ ng/mL} \pm 0.4 \text{ ng/mL}$ ($p = 0.592$) in the placebo group. No statistically significant difference in the change of antioxidant activity was observed between the two groups ($p = 0.916$; Fig. 4).

3.5. Fatigue Severity Scale

The mean fatigue scores from baseline to after 3 wk changed as follows: from 33.0 ± 11.6 to 24.3 ± 8.4 ($p < 0.001$) in the KRG group and from 29.8 ± 14.1 to 25.9 ± 12.5 ($p = 0.024$) in the placebo group. No statistically significant difference was found in the change of fatigue scores between the two groups ($p = 0.221$; Fig. 5). In patients with a BMI of 25 kg/m^2 or more who received KRG treatment, the mean fatigue scores showed particular improvement (from 35.0 ± 13.2 to 24.5 ± 8.9 ; $p = 0.003$). However, no significant change was observed in patients with a BMI less than 25 kg/m^2 in the KRG group, who had mean fatigue scores of 27.3 ± 5.3 at the baseline and 23.1 ± 8.0 at 3 wk ($p = 0.166$; Fig. 5).

4. Discussion

Our study demonstrated that fatigue severity significantly decreased between Day 0 and Day 21 in both the KRG and placebo groups. Interestingly, only overweight patients in the KRG group experienced a more significant decrease in their fatigue scores. A previous report suggested that *P. ginseng* Meyer is effective in

treating idiopathic chronic fatigue patients [18]. Until now, however, no study has assessed the efficacy of *P. ginseng* Meyer in treating fatigue in overweight patients. Based on the results of this study, it is concluded that KRG is effective in treating fatigue in NAFLD patients, especially in overweight patients.

Outpatients follow-up in this study was performed by one clinician, who advised the patients to exercise regularly and eat healthily, and prescribed Legalon (mainly *S. marianum*) to all patients. Previously, lifestyle modifications involving diet and exercise reduced the body weight of NAFLD patients to 5% [19]. The NAFLD activity scores improved in 67% of NAFLD patients after 2 yr of exercise and diet modification [20]. *S. marianum* has been used in many countries to treat patients with various liver diseases [21,22]. Our study also revealed the improvement in serum biochemical parameters (AST and ALT) for patients in the placebo group who received counseling for lifestyle modifications and Legalon. Taken together, lifestyle modifications and *S. marianum* might be recommended for NAFLD patients for the improvement of hepatitis.

In the KRG group, biochemical parameters such as AST, ALT, and γ -GT were significantly decreased after 3 wk of KRG treatment. We found that the decreases in ALT and γ -GT levels were more significant in patients with a BMI of 25 kg/m^2 or more in the KRG group than among overweight patients in the placebo group. Previous research has shown that *P. ginseng* improves insulin resistance and decreases ALT levels in rats with liver fibrosis [23,24]. Other studies have demonstrated that KRG extract decreases γ -GT levels in rats with alcohol-induced liver damage [25]. Results from previous studies and this study suggest that KRG alleviates hepatotoxicity, and is especially effective in overweight patients.




Fig. 5. Changes in Fatigue Severity Scale. In patients with a BMI of 25 kg/m^2 or more who received KRG treatment, the mean fatigue scores showed particular improvement. BMI, body mass index; KRG, Korean Red Ginseng; ns, not significant.

Adiponectin levels are related to metabolic syndrome and fatty liver disease [26]. Previous research has shown that treating adipocyte cells with *P. ginseng* extract increases adiponectin levels [27]. Similar results were found in studies using mice fed with a high-fat diet and treated with KRG. Increased adiponectin levels were observed in the serum of treated mice that were fed a high-fat diet [28]. Our study demonstrated that serum adiponectin levels increased in the KRG group, suggesting that KRG is an effective treatment for fatty liver disease.

KRG has been recognized as a natural substance with anti-inflammatory effects. Quan et al [29] demonstrated that streptozotocin-induced diabetic rats treated with 100 mg/kg of KRG showed lower serum TNF- α levels. Mice with acute liver failure have increased plasma TNF- α levels, which decrease after treatment with ginsenoside Rg1 [30]. In addition, it has been shown that ginsan (isolated from aqueous Korean *P. ginseng* extract) therapy can reduce TNF- α levels in healthy volunteers [31]. Based on these results, we suggest that KRG has significant anti-inflammatory activity.

It was reported that structures produced by adipocytes are homologous to adiponectin and TNF- α and are antagonistic to the insulin-modulating effects of these compounds [26,32]. In this study, patients with a BMI of 25 kg/m² or more showed a significant increase in serum adiponectin levels compared to patients with a BMI less than 25 kg/m². In addition, overweight patients treated with KRG had significantly decreased TNF- α levels. In light of these findings, we suggest that KRG may be a useful therapeutic agent for treating fatty liver disease, especially in overweight patients.

We did not observe changes in the IL-6 level. However, IL-6 levels have been shown to decrease in lipopolysaccharide-treated THP-1 macrophages treated with *Panax notoginseng* [33]. Another study found that *P. notoginseng* saponins downregulated IL-6 in rats with liver fibrosis [33]. For the evaluation of exact mechanism of KRG, more research is required to further investigate the therapeutic effect of KRG on IL-6 levels.

One limitation of our study is that we did not obtain a liver biopsy from each patient. Instead, we selected patients who had been diagnosed with fatty liver and hepatitis by blood tests, a medical history, and abdominal ultrasound. We followed the clinical practice guidelines of the Korean Association for the Study of the Liver, which indicated that NAFLD can be diagnosed by abnormal findings on liver function tests, along with a medical history, serological testing, and abdominal ultrasonography [34].

In conclusion, KRG reduced TNF- α serum levels and increased adiponectin serum levels in patients with NAFLD. KRG has anti-inflammatory effects, and is especially effective in overweight patients. Based on these results, we conclude that it is effective to treat overweight patients with NAFLD with *S. marianum*, nutrition and exercise therapy, and KRG.

Conflicts of interest

The authors declare that there is no conflict of interest, including relevant financial interests, activities, relationships, affiliations, and any other conflict of interest as explicitly and implicitly expressed in the Editorial Policies for Authors.

Acknowledgments

We would like to thank C.W. Kim, Y.J. Lee (Department of Internal Medicine, Hallym University College of Medicine), who made this study possible. This research was supported by a grant from the Korea Society of Ginseng funded by Korea Ginseng Corporation (Korean Red Ginseng; 2011), by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and

Technology (NRF-2010-0021482), and Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ009859) Rural Development Administration, Republic of Korea. This research was supported by Hallym University Research Fund.

Authors' contributions

M.H., Y.H.L., and S.K. contributed equally to this study. M.H., Y.H.L., S.K. contributed to the analysis, interpretation, collection, and assembly of data, as well as to the drafting of this article; K.T.S. contributed to the conception and design, critical revision of the article for important intellectual content, and final approval of the article; other authors contributed to the provision of study materials or patients.

References

- Brunt EM. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. *Dig Dis* 2012;30:61–8.
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41:1313–21.
- Review Team, LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *J Clin Gastroenterol* 2014;48:467–73.
- Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. *Gut* 2008;57:807–13.
- Morris G, Berk M, Walder K, Maes M. Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. *BMC Med* 2015;13:28.
- Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. *Hepatology* 2003;37:917–23.
- Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? *World J Gastroenterol* 2014;20:9217–28.
- Jarosz PA, Davis JE, Yarandi HN, Farkas R, Feingold E, Shippings SH, Smith AL, Williams D. Obesity in urban women: associations with sleep and sleepiness, fatigue and activity. *Womens Health Issues* 2014;24:e447–54.
- Hong SH, Suk KT, Choi SH, Lee JW, Sung HT, Kim CH, Kim EJ, Kim MJ, Han SH, Kim MY, et al. Anti-oxidant and natural killer cell activity of Korean Red Ginseng (*Panax ginseng*) and ursholol (*Rhus vernicifera* Stokes) on non-alcoholic fatty liver disease of rat. *Food Chem Toxicol* 2013;55:586–91.
- Bang CS, Hong SH, Suk KT, Kim JB, Han SH, Sung H, Kim EJ, Kim MJ, Kim MY, Baik SK, et al. Effects of Korean Red Ginseng (*Panax ginseng*), ursholol (*Rhus vernicifera* Stokes), and probiotics (*Lactobacillus rhamnosus* R0011 and *Lactobacillus acidophilus* R0052) on the gut-liver axis of alcoholic liver disease. *J Ginseng Res* 2014;38:167–72.
- Shen L, Xiong Y, Wang DQ, Howles P, Basford JE, Wang J, Xiong YQ, Hui DY, Woods SC, Liu M. Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats. *J Lipid Res* 2013;54:1430–8.
- Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, McGinn TW, Stella PJ, Seeger GR, Sood A, et al. Wisconsin Ginseng (*Panax quinquefolius*) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. *J Natl Cancer Inst* 2013;105:1230–8.
- Ginseng helps cancer-related fatigue. *Mayo Clin Health Lett* 2012;30:4.
- Choi JY, Woo TS, Yoon SY, Ike Campomayor Dela P, Choi YJ, Ahn HS, Lee YS, Yu GY, Cheong JH. Red ginseng supplementation more effectively alleviates psychological than physical fatigue. *J Ginseng Res* 2011;35:331–8.
- Katz P, Margaretten M, Trupin L, Schmajuk G, Yazdany J, Yelin E. Sleep disturbance, depression, obesity, and physical inactivity explain a significant portion of fatigue in rheumatoid arthritis. *Arthritis Care Res* 2016;68:81–90.
- Brainina KhZ, Ivanova AV, Sharafutdinova EN, Lozovskaya EL, Shkarina EL. Potentiometry as a method of antioxidant activity investigation. *Talanta* 2007;71:13–8.
- Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. *Arch Neurol* 1989;46:1121–3.
- Kim HG, Cho JH, Yoo SR, Lee JS, Han JM, Lee NH, Ahn YC, Son CG. Antifatigue effects of *Panax ginseng* C.A. Meyer: a randomised, double-blind, placebo-controlled trial. *PLoS One* 2013;8:e61271.
- Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, Jung DH, Kim KH, Yu E, Shim JH, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: analysis of biopsies of living liver donors. *J Gastroenterol Hepatol* 2012;27:1341–7.

- [20] Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010;51:121–9.
- [21] Ball KR, Kowdley KV. A review of *Silybum marianum* (milk thistle) as a treatment for alcoholic liver disease. *J Clin Gastroenterol* 2005;39:520–8.
- [22] Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and *Silybum marianum* extracts prevent liver damage. *Food Chem Toxicol* 2010;48:803–6.
- [23] Niranjana Murthy H, Dandin VS, Yoeup Paek K. Hepatoprotective activity of ginsenosides from *Panax ginseng* adventitious roots against carbon tetrachloride treated hepatic injury in rats. *J Ethnopharmacol* 2014;158:442–6.
- [24] Zhang SS, Wu ZY, Chen JM, Guo QK, Li L, Wang ZF, Gao Y, Ma ZC. Study on the mechanism of action of total saponins of *Panax notoginseng* in ameliorating oxidative stress and insulin resistance in rats fed with high fat diet. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2014;34:56–61.
- [25] Seo SJ, Cho JY, Jeong YH, Choi YS. Effect of Korean Red Ginseng extract on liver damage induced by short-term and long-term ethanol treatment in rats. *J Ginseng Res* 2013;37:194–200.
- [26] Lihn AS, Pedersen SB, Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. *Obes Rev* 2005;6:13–21.
- [27] Yeo CR, Yang C, Wong TY, Popovich DG. A quantified ginseng (*Panax ginseng* C.A. Meyer) extract influences lipid acquisition and increases adiponectin expression in 3T3-L1 cells. *Molecules* 2011;16:477–92.
- [28] Song YB, An YR, Kim SJ, Park HW, Jung JW, Kyung JS, Hwang SY, Kim YS. Lipid metabolic effect of Korean Red Ginseng extract in mice fed on a high-fat diet. *J Sci Food Agric* 2012;92:388–96.
- [29] Quan HY, Kim do Y, Chung SH. Korean Red Ginseng extract alleviates advanced glycation end product-mediated renal injury. *J Ginseng Res* 2013;37:187–93.
- [30] Zhao J, Shi Z, Liu S, Li J, Huang W. Ginsenosides Rg1 from *Panax ginseng*: a potential therapy for acute liver failure patients? *Evid Based Complement Alternat Med* 2014;2014:538059.
- [31] Cho YJ, Son HJ, Kim KS. A 14-week randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of ginseng polysaccharide (Y-75). *J Transl Med* 2014;12:283.
- [32] Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. *Trends Endocrinol Metab* 2002;13:84–9.
- [33] Fan JS, Liu DN, Huang G, Xu ZZ, Jia Y, Zhang HG, Li XH, He FT. *Panax notoginseng* saponins attenuate atherosclerosis via reciprocal regulation of lipid metabolism and inflammation by inducing liver X receptor alpha expression. *J Ethnopharmacol* 2012;142:732–8.
- [34] Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. *Clin Mol Hepatol* 2013;19:325–48.